目的：在已建立“血红蛋白释放试验HRT”的基础上，研究肿瘤患者的HRT情况。方法同时比较研究全血中红细胞和从中分离出来红细胞的HRT（简称“两种红细胞的HRT”），做淀粉-琼脂糖混合凝胶电泳。第1次电泳后停电一段时间，再进行第2次或更多次电泳。观察红细胞中血红蛋白的释放情况，同时加入了定量因素。结果各种肿瘤标本都有“两种红细胞的HRT”，梯带强度可有不同。本次标本中，游离红细胞梯带相对最强的是肝癌、胰腺癌、胃癌，最弱的是鼻咽癌、甲状腺癌、皮肤癌。全血红细胞的梯带强度普遍较弱，变化相对较小。结论肿瘤患者标本中的血浆因素可能影响全血中红细胞的梯带释放。不同肿瘤其血浆因素可能不一样，具体机制有待深入研究。%Objective To study the hemoglobin release test in different cancer patients on the basis of hemoglobin release test.Methods Comparative study of red blood cells in whole blood and extracted from red cell HRT(referred to as the "two red cell HRT")was carried out with starch-agarose mixed gel electrophoresis. After ifrst run of electrophoresis, the power was cut down for a while, the second run of electrophoresis was then performed. Observe the release of hemoglobin in red blood cells with the quantitative factors.Results There are "two red cell HRT" in all tumors, and maybe have different ladder intensity. The ladder intensity of free erythrocyte in liver cancer, pancreatic cancer, gastric cancer and nasopharyngeal carcinoma are strongest. The weakest is thyroid cancer, skin cancer. The ladder intensity of red blood cells is generally weak, and has small changes.Conclusion There are some plasma factor specimens in cancer patients affect red cells in blood ladder release. Different tumor plasma factors may not be the same, the mechanism need to be further studied.
展开▼
